ARCHIVES

Nixon Resignation Won’t Hurt Cancer Program, Might Lead To More Money; Weinberger Stays

This article is from The Cancer Letter archive.

Vol. 01 No. 28 | August 16, 1974

Download PDF Visit The Full Archive

Related Articles

Campath Improves PFS In B-Cell CLL In Phase III Trial

January 26, 2007

Former NCI, FDA Chief Andrew Von Eschenbach Appointed to NCCN Foundation Board

June 17, 2011

CMS Unable to Adjust Cuts To Cancer Care

June 7, 2013

Phase III Trial Retrospective Analysis Finds Talimogene Laherparepvec Reduced Tumors

March 28, 2014

Arzerra Maintenance Therapy Extends PFS In Phase III Trial, Compared to Observation

August 29, 2014

In Brief: NCAB Approves Concept Of Converting Baltimore Program To Cancer Center; New DCCP Labs Named

June 5, 1981